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Pepducins constitute a unique class of G-protein coupled receptor (GPCR) modulating lipopeptides.
Pepducins with inhibitory effects on neutrophils could potentially be developed into
anti-inﬂammatory pharmaceuticals. A pepducin with a peptide sequence identical to the third
intracellular loop of FPR1 was found to inhibit neutrophil functions including granule mobilization
and superoxide production. This FPR1-derived pepducin selectively inhibited signaling and cellular
responses through FPR2, but not FPR1 as expected. Binding to the neutrophil surface of a conven-
tional FPR2 agonist is also inhibited. The fatty acid is essential for inhibition and pepducins with
shorter peptides lose in potency. In summary, a pepducin designed to target FPR1 was found to
hijack FPR2 and potently inhibit neutrophil functions.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The inﬂammatory response constitute an important part of our
innate immunity system, but unbalanced or prolonged, inﬂamma-
tion can be detrimental to the host [1]. Immunomodulation has
been proposed as an anti-inﬂammatory therapeutic approach and
as neutrophils are important effector cells and the ﬁrst cells to be
recruited to inﬂammatory sites, these cells have become an attrac-
tive target for drug development [2–4]. Recruitment and activation
of neutrophils occur through integration of signals from
cell-surface G-protein coupled receptors (GPCRs) recognizing
endogenous or microbial derived chemoattractants such as
N-formylated peptides recognized by formyl peptide receptors
(FPRs) [5,6]. Pepducins, lipopeptides composed of a fatty acidconjugated with a short peptide, activate or inhibit signaling of
GPCRs [7,8]. The peptide in a given pepducin has an amino acid
sequence identical to one of the intracellular domains of the recep-
tor aimed to be targeted, and this is the basis for the suggestion
that pepducins interact directly with a cytosolic receptor domain
and thereby activate or inhibit the functions of the targeted recep-
tor [7,9]. Many receptor-speciﬁc pepducins have been identiﬁed,
and their therapeutical potentials have been explored with promis-
ing results [7,10,11] and they represent a novel allosteric approach
to modulation of GPCR signaling. Activating pepducins highly
speciﬁc for formyl peptide receptor 2 (FPR2) were recently
described [12,13]. The two FPRs expressed in human neutrophils
(FPR1 and FPR2) share a large sequence similarity (69% amino acid
identity) [5,6], but the FPR2 pepducins showed no cross activation
of FPR1 [13–15]. The two receptors utilize very similar signaling
pathways [16], but the recent disclosure of some fundamental dif-
ferences [13,17] suggests that the two neutrophil FPRs are not
redundant and they may have different roles in inﬂammation
and/or innate immunity.
In this study, we aimed to gain more insight into the FPR signal-
ing in regulating neutrophil functions, using pepducins as unique
research tools. We found that a pepducin derived from the third
intracellular loop of FPR1 inhibited neutrophils but the target
was not FPR1. The FPR1 pepducin instead hijacked the closely
related FPR2.
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2.1. Chemicals
Horseradish peroxidase (HRP), isoluminol, human recombinant
TNFa, formylated tripeptide fMLF and C5a were purchased from
Sigma–Aldrich (St. Louis, MO, USA). Ficoll paque was obtained from
GE Healthcare. The phenol-soluble modulin (PSMa2) in its
N-formylated form was obtained from American Peptide
Company (Sunnyvale, CA, USA) and the hexapeptides
WKYMWM/m were purchased from AltaBioscience (University of
Birmingham, Birmingham, U.K.). Compound 43 was a generous gift
from Anygen. The receptor antagonist WRWWWW (WRW4) was
from Genscript Corporation (Scotch Plains, NJ, USA) and cyclos-
porin H (CysH) was kindly provided by Novartis Pharma (Basel,
Switzerland). Phosphoinositide binding peptide 10 (PBP10) peptide
(RhB-QRLFQVKGRR), MMK-1, fMIFL, the pepducins and the
non-palmitoylated control peptide were obtained from Caslo
Laboratory (Lyngby, Denmark). The pepducins were synthesized
by Fmoc solid-phase peptide synthesis and the fatty acid were
N-terminally linked on the resin as the last step before deprotec-
tion of side chains, followed by HPLC puriﬁcation on a C18 column
and further veriﬁcation by MALTI-TOF Mass Spectrometry. The
Cy5-WKYMWM peptide and FITC-fNLFNYK peptides were from
Phoenix Pharmaceutical (Burlingame, CA). All peptides were dis-
solved in DMSO to a stock concentration of 10 mM and stored at
80 C. Further dilutions were made in Krebs–Ringer phosphate
buffer (KRG) supplemented with glucose (10 mM), Ca2+ (1 mM),
and Mg2+ (1.5 mM) (KRG; pH 7.3).
2.2. Isolation of human neutrophils
Human polymorphonuclear neutrophils were isolated from
buffy coats obtained from healthy adults as described [18]. Each
independent experiment was performed on neutrophils isolated
from an individual blood donor (n > 3). After hypotonic lysis, the
neutrophils were washed twice, resuspended (1  107/mL) in
KRG and, kept on melting ice until use.
2.3. Over-expression of FPR1 and FPR2 in HL-60 cells
The procedures used to obtain stable expression of FPR1 and
FPR2 in undifferentiated HL-60 cells have been previously
described [19]. At each passage, an aliquot of the cell culture was
centrifuged, the supernatant was discarded and the cell pellet
was resuspended in fresh medium RPMI 1640 containing FCS
(10%), PEST (1%), and G418 (1 mg/ml).
2.4. Neutrophil NADPH-oxidase activity
The release of superoxide anion upon NADPH-oxidase activa-
tion was determined by an isoluminol-enhanced chemilumines-
cence (CL) system using a 6-channel Biolumat LB 9505 (Berthold
Co, Wildbad, Germany) as described [20,21]. The neutrophils in
measuring vials were pre-warmed for 5 min at 37 C in the pres-
ence or absence of receptor inhibitors, after which the stimulus
was added and superoxide production was recorded continuously.
2.5. Changes in the cytosolic concentration of free Ca2+
Neutrophils freshly isolated from buffy coats (5  107/mL) or
HL-60 cells overexpressing FPRs (5  107/ml) were labeled with
Fura 2-AM (Molecular Probes, Eugene, OR, USA), and the transient
rise in cytosolic Ca2+ concentration was determined using a
PerkinElmer ﬂuorescence spectrophotometer (LC50). For studieswith inhibitors, the cells were pre-incubated with the inhibitors
during the pre-warming period for 10 min before addition of the
stimulus. The relative intracellular Ca2+ concentration is presented
as the ratio between ﬂuorescence intensities of the emitted light at
340 nm and 380 nm when excited at 510 nm.
2.6. Surface CR3 expression
The level of surface expression of CD11b/CR3 was determined
using a phycoerythrin (PE)-conjugated antibody against CR3 (BD
Biosciences, MD, USA). Cells in KRG (106/mL) were incubated with
or without inhibitors at 37 C for 5 min followed by stimulation
with ligands and the incubation was continued for another
10 min. Cells were stained with antibody against CR3 or isotype
control for 30 min on ice and binding analyzed by ﬂow cytometry
using an Accuri C6 (Becton Dickinson Sparks, MD, USA).
Neutrophils were gated based on forward and side scatter.
2.7. Effect of the F1Pal16 pepducin on FITC-fNLFNYK (FPR1 speciﬁc) and
Cy5-WKYMVM (FPR2 speciﬁc) binding to neutrophils
Neutrophils in ice cold KRG (106/mL) were pre-incubated with
unlabeled WKYMVM, or F1Pal16 for 5 min before addition of the
ﬂuorescently labeled FPR2-speciﬁc agonist (Cy5-WKYMWM,
1 nM) or the FPR1-speciﬁc agonist (FITC-fNLFNYK, 1 nM) and the
incubation was continued for another 60 min. The amount of
bound peptide was analyzed by ﬂow cytometry.
2.8. Statistical analysis
Statistical analysis was performed in Graph Pad Prism 6.0
(Graphpad Software, San Diego, CA, USA).3. Results
3.1. No FPR1 related inhibition or activation is induced in neutrophils
by the F1Pal16 pepducin
Pepducins have been identiﬁed and characterized as either
activating or inhibiting modulators in relation to their respective
GPCR [7]. We have previously identiﬁed neutrophil-activating
pepducins derived from FPR2, and the most potent pepducin was
F2Pal10, spanning the amino acids K227 to S236 (KIHKKGMIKS) in
the third intracellular loop of FPR2 [13]. The third intracellular
loop of FPR1 is very similar, differing in only two amino acids.
We now conﬁrm that the F1Pal16 pepducin (F1Pal16,
Pal-KIHKQGLIKSSRPLRV; spanning the entire third intracellular
loop of the receptor), in contrast to the corresponding FPR2 pep-
ducin, lacked direct neutrophil activating effect, revealed by the
inability of the pepducin to trigger superoxide anion production
at concentrations up to 5 lM ([13], Fig. 1A inset). It is known that
the level of superoxide production from neutrophils is largely
dependent on the cellular state, with naïve neutrophils producing
low levels of ROS and primed cells producing high levels of ROS
[22], but not even neutrophils primed with TNFa produced super-
oxide upon stimulation with F1Pal16 (data not shown).
We next took the inhibitor approach and investigated whether
the F1Pal16 pepducin could negatively modulate the
FPR1-mediated response. The inhibitory effect of the established
FPR1-antagonist CysH was conﬁrmed (included as control with
an FPR1 agonist in Fig. 1A). Conversely, F1Pal16 did not affect the
fMLF response (Fig. 1A). In summary, we show that F1Pal16 has
no modulating (neither activating nor inhibitory) effects related
to FPR1 signaling.
Fig. 1. The F1Pal16 pepducin inhibits superoxide production induced by the FPR2 agonists but not the FPR1 agonist fMLF in human neutrophils. (A) Neutrophils were pre-
warmed at 37 C for 5 min in the presence of the FPR1 antagonist CysH (1 lM, dotted line) or F1Pal16 (1 lM, dashed line) before stimulation with the FPR1-speciﬁc agonist
fMLF (50 nM). Control cells (solid line) were incubated in the absence of antagonist. The inset shows the direct neutrophil activation capacity of the FPR1 pepducin F1Pal16
(5 lM, broken line) compared to the FPR1 agonist fMLF (50 nM, solid line). The release of superoxide anions was measured continuously. The arrows indicate the time points
for stimulus addition. Representative experiments out of more than three are shown. Abscissa, time of study (min); ordinate, superoxide production in Mcpm (arbitrary
units). (B, C) Neutrophils were pre-incubated at 37 C for 5 min in the presence (broken line) or absence (solid line) of F1Pal16 (500 nM). The FPR2-speciﬁc peptide agonist
WKYMVM (50 nM; B) or the FPR2 activating pepducin F2Pal10 (500 nM; C) was then added to the cells and the release of superoxide anions was measured continuously.
Abscissa, time of study (min); ordinate, superoxide production in Mcpm (arbitrary units). The arrows indicate the time point for the addition of stimuli. A representative
experiment out of more than three is shown.
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mediated through FPR2
A pepducin is assumed to interact with receptors that contain
an amino acid sequence identical to that of the pepducin [7].
FPR1 and FPR2 share large sequence similarity in their signaling
domains and transduce very similar signaling pathways although
differences have been observed [17]. Since this FPR1 derived pep-
ducin has no effect on FPR1 signaling, we next examined whether
it could interfere with signaling by the closely related FPR2. F1Pal16
inhibited the response in neutrophils induced by the conventional
peptide agonist WKYMVM (Fig. 1B). Based on the fact that the third
intracellular loops of FPR1 and FPR2 are very similar, we hypothe-
sized that F1Pal16 may interfere with the activity induced also by
FPR2 pepducins. To examine this, neutrophils pre-incubated with
F1Pal16 were stimulated with the FPR2 activating pepducin
F2Pal10 and F1Pal16 was found to inhibit also this response
(Fig. 1C).
Our data show that the F1Pal16 pepducin lacks modulatory
effect on FPR1 but inhibits the activity of FPR2 induced by both a
conventional peptide agonist and the recently described activating
pepducin. This fact promotes us to examine whether F1Pal16
causes a general inhibition of FPR2-mediated signals. To address
whether also the response induced by other FPR2 agonists was
affected, the activating FPR2 pepducin was replaced with several
other earlier described FPR2 agonists. Similar to the data obtained
with the conventional peptide agonist WKYMVM and the
FPR2-activating pepducins, F1Pal16 inhibited superoxide produc-
tion upon stimulation with all FPR2 agonists examined (Fig. 2A),
strongly suggesting that F1Pal16 is a general FPR2-speciﬁc
inhibitor.That FPR2 is the receptor utilized by F1Pal16 gained further sup-
port from studies using dual receptor agonists displaying binding
afﬁnities for both FPR1 and FPR2. It is known that the neutrophil
response induced by dual agonists such as WKYMVm, Compound
43 and fMIFL-PSM5-16 cannot be inhibited by CysH (an FPR1 antag-
onist) or PBP10 (an FPR2 inhibitor) alone [23–25], but for a sub-
stantial inhibition the two antagonists have to be present
together. In line with this, we found that neither F1Pal16 (FPR2
inhibitor) nor CysH (FPR1 inhibitor) alone caused any substantial
inhibition of the neutrophil response induced by the dual agonist
fMIFL-PSM5-16 (Fig. 2B); when F1Pal16 was used in combination
with CysH, the response was, however, completely abolished
(Fig. 2B). These data thus support the FPR2 selectivity of the
FPR1 pepducin F1Pal16, and additional support was obtained from
the fact that no inhibitory effect was seen with F1Pal16 on the neu-
trophil response induced by the high afﬁnity FPR1 agonist fMIFL
(derived from Staphylococcus aureus) or complement factor C5a
binding to the C5a receptor (Fig. 2A).
3.3. The inhibitory potency of F1Pal16 is comparable to that of the
PBP10 peptide
Several FPR2-selective antagonists/inhibitors have been
described during the last years, including the ﬁrst reported peptide
antagonist WRW4 (identiﬁed through a peptide library screen;
[26], the gelsolin-derived peptide PBP10 [17], and a recently
described proteolytic stable peptidomimetic [25]. The neutrophil
response induced by the FPR2 agonist WKYMVM was dose depen-
dently inhibited by the F1Pal16 pepducin with an IC50 value in the
low nM range (Fig. 3). Comparing the potency of the FPR2-speciﬁc
F1Pal16 pepducin to that of the most potent earlier described
Fig. 2. The FPR1 pepducin F1Pal16 inhibits superoxide production induced by conventional FPR2 agonists. (A) Neutrophils were pre-incubated in the absence or presence of
F1Pal16 pepducin (500 nM) at 37 C for 5 min upon stimulation. The various FPR1- or FPR2-speciﬁc or dual FPR1/FPR2 agonists used were; MMK1 (200 nM), WKYMVM
(50 nM), PSMa2 (50 nM), F2Pal10 (500 nM), WKYMVm (50 nM), fMIFL-PSM5-16 (2 nM), Compound 43 (1 lM), fMIFL (1 nM), and fMLF (50 nM). The C5aR agonist C5a (1 ng/ml)
was used as a non-FPR agonist control. The release of superoxide anion was measured. The F1Pal16 effect is expressed as percent of remaining activity (peak superoxide anion
response) when compared to the response in neutrophils activated with the same receptor agonist in the absence of F1Pal16 (mean + S.D.; n > 3). (B) The inhibitory effect of
F1Pal16 on FPR2 was examined using the dual FPR1/FPR2 agonist fMIFL-PSM5-16 (2 nM). Cells were incubated at 37 C for 5 min with the FPR1 antagonist CysH (1 lM, dashed
line) or F1Pal16 (1 lM, dotted line) or both inhibitors together before stimulation with the dual agonist. The response induced by fMIFL-PSM5-16 in neutrophils incubated
without any inhibitor (solid line) is shown for comparison. The release of superoxide was measured continuously. Abscissa, time of study (min); ordinate, superoxide
production in Mcpm (arbitrary units). The arrow indicates the time point for the addition of stimulus. A representative experiment out of three is shown.
Fig. 3. The inhibitory potency of F1Pal16 is comparable to that of the PBP10 peptide.
Human neutrophils were incubated with various concentrations of F1Pal16 (circles),
PBP10 (squares) or WRW4 (triangles). The cells were then activated with the FPR2
agonist WKYMVM (50 nM) and the production of superoxide was recorded
continuously. The inhibition is expressed as the remaining neutrophil response
(peak values) in the presence of the different inhibitors when compared to the
control WKYMVM response obtained in the absence of any inhibitor. Abscissa,
concentration of inhibitor; ordinate, peak value of superoxide production (percent
of control; (mean + S.D.; n > 3).
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same range as that of PBP10 (IC50  10 nM; Fig. 3). The conven-
tional peptide antagonist WRW4 (IC50  450 nM) was not as potent
as the pepducin (Fig. 3).
3.4. The F1Pal16 pepducin inhibits the transient rise in cytosolic free
Ca2+ and granule mobilization in neutrophils induced by the FPR2
agonist WKYMVM
One of the early signaling pathways activated by the agonist
occupied FPRs is the PLC-IP3 pathway leading to a release of Ca2+
from intracellular stores and consequently an increase in the
cytosolic concentration of free Ca2+ [5]. In accordance with the data
showing that F1Pal16 targets the cellular responses induced by
FPR2 agonists at the level of the receptor, also the rise in cytosolic
Ca2+ induced by the FPR2 agonist WKYMVM was inhibited in cellspre-treated with F1Pal16 (Fig. 4A). On the other hand, the transient
rise in intracellular Ca2+ induced by the FPR1 agonist fMLF was not
affected by F1Pal16 (Fig. 4A), but as expected this response was
inhibited by the FPR1 antagonist CysH (data not shown). The
notion that F1Pal16 pepducin interferes with FPR2 but not FPR1
gained further support from experiments performed on undiffer-
entiated HL-60 cells over-expressing the two FPRs, showing that
F1Pal16 inhibited the signaling in FPR2- but not
FPR1-overexpressing cells when activated with their respective
agonists (Fig. 4B).
Signals in neutrophils generated by FPR1- as well as
FPR2-speciﬁc agonists mobilize granule-localized receptors such
as CR3 (the CD11b/CD18 complex) to the plasma membrane
[6,19]. We investigated whether F1Pal16 could also inhibit
FPR2-mediated granule mobilization. Neutrophils activated with
fMLF or WKYMVM, agonists for FPR1 and FPR2, respectively, mobi-
lized their granules as evidenced by an increased surface expres-
sion of CD11b (Fig. 4C). In line with the inhibitory pattern
observed for F1Pall6 in superoxide production and Ca2+ signaling,
F1Pal16 dose-dependently inhibited CR3 up-regulation triggered
by WKYMVM, while no such inhibitory effect was seen when
fMLF was used as the secretagogue (Fig. 4C). F1Pal16 did not in
itself trigger any increased surface expression of CR3 (data not
shown). Taken together, these data suggest that the FPR1 pepducin
F1Pal16 hijacks the closely related FPR2 and affects signaling and
the downstream effector responses through FPR2 in neutrophils.
3.5. The F1Pal16 pepducin competes with a conventional FPR2 agonist
for binding
Pepducins have been proposed to target receptors through
interactions with cytosolic parts of the receptor in a process not
affecting the binding of conventional peptide agonists [7,27]. To
further elucidate the mechanism of action of F1Pal16, binding
experiments were performed in which the F1Pal16 pepducin was
allowed to compete with a ﬂuorescently labeled conventional
FPR2 agonist (Cy5-WKYMVM) for binding to neutrophils. The
presence of an excess of non-labeled WKYMVM largely inhibited
binding of the ﬂuorescently labeled Cy5-WKYMVM (Fig. 5),
illustrating that Cy5-WKYMVM binds speciﬁcally to FPR2. The
presence of F1Pal16 also reduced Cy5-WKYMVM binding in a
Fig. 4. The F1Pal16 pepducin inhibits WKYMVM-induced Ca2+ transients and granule mobilization. (A) Fura-2 loaded neutrophils were pre-incubated at 37 C for 10 min in
the absence (solid line) or presence (dashed line) of F1Pal16 (1 lM) followed by stimulation with FPR2 agonist WKYMVM (10 nM). The insert shows neutrophils stimulated
with FPR1 agonist fMLF (10 nM) in the absence (solid line) or presence (dashed line) of F1Pal16 (1 lM). (B) Fura-2 loaded HL-60 cells over-expressing FPR2 were pre-incubated
at 37 C for 10 min in the absence (solid line) or presence (dashed line) of F1Pal16 (500 nM) followed by stimulation with FPR2 agonist WKYMVM (5 nM). The insert shows HL-
60 cells over-expressing FPR1 stimulated with FPR1 agonist fMLF (5 nM) in the absence (solid line) or presence (dashed line) of F1Pal16 (500 nM). The transient change in
cytosolic Ca2+ was monitored by the Fura-2 ﬂuorescence emitted at 509 nmwhen excited at 340 nm and 380 nm. The time points for agonist addition are indicated by arrows.
Traces of representative Ca2+ responses (ratio between the ﬂuorescence intensities at 340 nm and 380 nm) are shown. Abscissa, time of study (sec); ordinate, ﬂuorescence
(arbitrary units). Representative experiments out of more than three are shown. (C) Neutrophils pre-incubated at 37 C for 5 min in the presence or absence of various
concentrations of F1Pal16 were stimulated with fMLF (50 nM, white bar) or WKYMVM (50 nM, black bars) for 10 min at 37 C. The cells were then stained for surface
expression of CR3 using a ﬂuorescent antibody directed against CD11b, and analyzed by ﬂow cytometry. Data are expressed as percent of surface CR3 expression (MFI) when
compared to control cells which received either WKYMVM or fMLF alone without F1Pal16 (mean + S.D.; n = 3). The inset shows a representative histogram of CR3 ﬂuorescence
from WKYMVM stimulated cells either alone (solid line) or in the presence of F1Pal16 (500 nM, dashed line). CR3 ﬂuorescence in untreated cells (incubated under the same
conditions) is shown in gray.
Fig. 5. The F1Pal16 pepducin inhibits Cy5-WKYMVM surface binding to neutrophils.
Neutrophils were pre-incubated on ice for 5 min with two different concentrations
of non-labeled WKYMVM and three different concentrations of F1Pal16 as indicated.
After which a ﬂuorescently labeled Cy5-WKYMVM (1 nM, white bars) was added
and incubated for 1 h before analysis by ﬂow cytometry. The effect of F1Pal16
(500 nM) on cell surface binding of the FPR1 agonist FITC-fNLFNYK (1 nM, black
bar) is shown as comparison. The inhibition is expressed as the ﬂuorescence
(expressed in percent) compared to that obtained with Cy5-WKYMVM or FITC-
fNLFNYK alone (mean + S.D., n = 3).
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tion of F1Pal16 used was as efﬁcient as the non-labeled
WKYMVM in inhibiting Cy5-WKYMVM binding (Fig. 5). The pres-
ence of F1Pal16 was without any effect on binding of the ﬂuores-
cently labeled FPR1 agonist FITC-fNLFNYK (Fig. 5). Taken
together, we show that F1Pal16 hijacks FPR2 and inhibits down-
stream signaling as well as the binding of a conventional FPR2 ago-
nist to the receptor.
3.6. The palmitoyl group of the pepducin is required and the
C-terminus part of the peptide chain is of importance for FPR2 inhibition
According to the suggested mode of action for pepducins, stip-
ulating that a fatty acid is required for anchoring the pepducin to
the plasma membrane and for peptide-induced intracellular inter-
action, the anchoring phase has to be followed by a translocation of
the peptide part of the pepducin over the membrane and to the
cytosol. In accordance with the suggested importance of the fatty
acid for pepducin activities [7], the F116 peptide, lacking the palmi-
toyl group, was completely inactive (Fig. 6A). To exclude the possi-
bility that the lack of inhibition was simply due to a restricted
diffusion of the naked peptide over the membrane, the concentra-
tion of F116 was increased to 10 lM (20 higher than that required
for F1Pal16 to induce inhibition), and no inhibitory effect was
observed (Fig. 6A). We have earlier shown that the potency of
the FPR2 activating pepducin F2Pal16 increase when the amino acid
Fig. 6. The fatty acid is required and the length of the peptide chain affects the inhibition induced by the F1Pal16 pepducin. (A) Human neutrophils were incubated with
F1Pal16 (500 nM; dotted line) or the corresponding non-palmitoylated peptide F116 (10 lM; dashed line) at 37 C for 5 min. The cells were than activated by an addition of
WKYMVM (50 nM) and the release of superoxide anions was monitored continuously. The time point for addition of WKYMVM is indicated by an arrow. A representative
experiment out of three is shown. Abscissa, time of study (min); ordinate, superoxide production in Mcpm (arbitrary units). (B) Neutrophils were incubated with different
concentrations of F1Pal16 (black) and the C-terminal truncated variants F1Pal14 (dark gray), F1Pal12 (gray) and F1Pal10 (white) at 37 C for 5 min. The cells were than activated
by an addition of WKYMVM (50 nM) and the release of superoxide anions was monitored continuously. The results are expressed as percent of the response (peak values)
induced by WKYMVM when added to cells incubated in the absence of pepducins (mean + S.D.; n = 3).
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pepducin to be the most potent one in this series [13]. In contrast,
successive C-terminal truncations of the inhibitory F1Pal16 reduced
the effect of this pepducin, suggesting that the C-terminus of the
peptide chain plays a role for the inhibition (Fig. 6B).4. Discussion
The discovery of a unique class of molecules named pepducins
has provided remarkable molecular tools for studies of signaling
through GPCRs [7]. A pepducin is composed of a fatty acid and a
peptide with an amino acid sequence identical to an intracellular
receptor domain, and according to the proposed mechanism of
action for this class of molecules, a pepducin speciﬁcally activates
or inhibits the receptor from which its peptide sequence is derived.
Our data show that the F1Pal16 pepducin derived from the third
intracellular loop of FPR1 potently inhibits neutrophil functions,
and the affected receptor was found to be FPR2 but not FPR1. A
similar type of unfaithfulness has been described for
b2-adrenergic receptor pepducins that modulate also b1-AR [28]
and a PAR1-derived pepducin which activates also the homologous
receptor PAR2 [27,29]. These data suggest that the concept of
inherent receptor selectivity for a given pepducin is not always
valid. Moreover, one of the criteria fulﬁlled for most pepducins is
that they do not compete in receptor binding with conventional
receptor ligands. It is clear from our data with the F1Pal16
pepducin, and also from earlier published data on FPR2 activating
pepducins [13,15], that the FPR pepducins compete in binding with
the conventional FPR2 agonists. The precise mechanisms for how
these pepducins affect binding of conventional agonists remains
to be disclosed. It is possible that there is not one single mecha-
nism by which pepducins selectively activate/inhibit GPCRs, and
one possible explanation to the results obtained on competition
of binding would be that also the F1Pal16 pepducin is recognized
by the agonist binding domain in FPR2 exposed on the cell surface.
This suggestion gains support not only from the fact that the
F1Pal16 pepducin affects binding of a conventional FPR2 agonist,
but also from earlier published data showing that the activity
induced by the FPR2 activating pepducin F2Pal10 is reversed by a
conventional peptide antagonist [15]. Another possibility would
be that F1Pal16 act as an allosteric modulator affecting FPR2 from
inside and induce a conformational change of the surface exposed
parts of the receptor, a change that results in reduced binding of aconventional agonist. This type of afﬁnity change has been
reported for FPR1 [30,31]. A direct interpretation of the lack of con-
sistency between the expected outcome of the experiments and
the results obtained would be that the peptide parts of the FPR2
pepducins interact with binding sites used also by conventional
FPR2 ligands. More studies are needed to elucidate the precise
mode of action for the FPR pepducins, but obviously different,
possibly unique, modes of action are utilized by each individual
pepducin/receptor pair. It is clear, however, that irrespectively of
the precise mechanism of action, the peptide part does not work
alone, the fatty acid has to be conjugated in order for the pepducin
to mediate its effects, and this is true for all pepducins described
including the FPR related ones [7,13,14]. It is believed that the fatty
acid acts as a membrane anchor that enables the peptide part of
the pepducin to enter the cytosol. The precise mechanisms for
how the membrane-binding and down-stream presentation steps
are achieved/regulated have not been elucidated at the molecular
level.
It is worth noting that the difference between the FPR pep-
ducins with opposite effects (activating verses inhibiting) at amino
acid level is one single amino acid [13,15] and it is intriguing how
the exchange of one positively charged residue for a neutral one
can transfer the pepducin from an activating to an inhibiting one.
Although no precise interaction site for any of the known pep-
ducins has been elucidated, this type of allosteric modulators are
supposed to interact directly with intracellular signaling receptor
domains [7]. Signaling modulation by the third intracellular loop
pepducin may, however, require not only this part of the receptor
but also other parts such as the C-terminal cytoplasmic tail of the
receptor [27,29]. The two FPRs share a large sequence homology in
the third intracellular loop and the largest divergence lies in the
cytoplasmic tail [17], suggesting that it is reasonable to hypothe-
size that the tail region is in some way involved in signaling.
Assuming that the interaction between the F1Pal16 pepducin and
FPR2 takes place on the inside of the plasma membrane and
involves the receptor parts exposed to the cytosolic, the structural
differences between the two receptors could not be determined by
the amino acid differences in the third intracellular loop alone but
also other receptor domains are of importance for the structure
that deﬁnes the pepducin sensitivity. This is in analogy with our
recent ﬁnding that structural changes in the agonist binding
domains in FPR1 exposed on the cells surface are induced by an
amino acid sequence change in the cytoplasmic tail, a part of the
receptor located at a distance from the binding domains and not
1838 M. Winther et al. / FEBS Letters 589 (2015) 1832–1839directly involved in binding [25]. It is also clear from earlier studies
that despite the large sequence similarities in the intracellular
domains of FPR1 and FPR2, the two receptors transduce distinct
signals [17].
Notable in GPCR biology is also the accumulating evidence
showing that GPCRs can form dimers and possibly even larger oli-
gomeric complexes, which may introduce new and unique ligand-
and G-protein-binding characteristics as well as signaling proﬁles
compared to the naïve receptor [32]. Receptor dimerization is
achieved through interactions/associations between intracellular
receptor loops, and this type of interaction forms thus a plausible
explanation to how pepducins can modulate receptor activity from
inside by mimicking a dimerization partner. With respect FPRs
dimerization the available information is limited but it has been
shown that no stable homodimers are formed by FPR1 [33,34]. It
was recently shown that FPR2 can form homodimers as well as
heterdimers with FPR1 [35] and whether this is of importance
for the effects induced by FPR pepducins remains to be determined.
We know, however, from our results obtained with HL-60 cells
over-expressing FPRs, that the F1Pal16 can inhibit FPR2 signaling
even without the expression of FPR1.
In summary, we introduce a neutrophil inhibitory pepducin
with a peptide sequence identical to that in the third intracellular
loop of FPR1. This pepducin inhibits FPR2 signaling but leaves FPR1
untouched. Although the precise mechanisms of action for the
FPR1 derived inhibitory pepducin as well as for the earlier
described FPR2 activating pepducins remain to be elucidated, these
molecules provide additional tools to study the role of FPR2 in
inﬂammation/innate immunity. Such tools can be employed to
generate knowledge that facilitates our understanding of GPCR
modulation in general, and could be used in the development of
future FPR2-based immunomodulatory therapeutics.
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